



Shaping Tomorrow's Nephrology: **Insight-Driven Kidney Care**

KSN SEOUL, KOREA
2026

The 46th Annual Meeting of the Korean Society of Nephrology



Jun 11(Thu) – 14 (Sun), 2026

COEX, Seoul, Korea

Lecture Code : SS03-S2

Session Name : Satellite Symposium 2 (Sponsored by HK inno.N)

Session Topic : A New Horizon in Renal Anemia: Global Insights and the Clinical Debut of Vadadustat

Date & Time, Place : June 12 (Fri) / 13:50-15:30 / Auditorium, 3F

Current Landscapes: Evolution of Global Guidelines in Renal Anemia Management

Marcello Tonelli

University of Calgary, Canada

Anemia is a common and clinically important complication of chronic kidney disease (CKD), affecting patients across the spectrum of disease severity and contributing to fatigue, reduced quality of life, increased cardiovascular risk, and higher health care utilization. Over the past three decades, approaches to the diagnosis and management of renal anemia have evolved substantially, driven by advances in pathophysiology, therapeutic options, and clinical trial evidence.

Early clinical practice guidelines focused primarily on the use of erythropoiesis-stimulating agents (ESAs) and iron supplementation to correct anemia and reduce transfusion requirements. Subsequent large randomized trials demonstrated important safety considerations related to hemoglobin targets and ESA dosing, leading to a shift toward more conservative treatment strategies and a greater emphasis on individualized therapy.

More recently, a growing understanding of iron metabolism, inflammation, and hypoxia signaling has expanded the therapeutic landscape. The development of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), along with improved approaches to iron therapy and anemia monitoring, has prompted a reassessment of optimal treatment strategies and guideline recommendations.

Global guideline organizations—including KDIGO and other regional nephrology societies—have periodically updated their recommendations to reflect evolving evidence and therapeutic options. These updates increasingly emphasize individualized treatment decisions, careful assessment of iron status, judicious use of ESAs, and appropriate integration of emerging therapies.

This lecture will review the historical evolution of international guidelines for renal anemia management and examine how recent scientific and therapeutic advances are shaping current

recommendations. Particular attention will be given to differences in regional practice patterns, areas of ongoing uncertainty, and the implications of emerging evidence for future guideline development.

Understanding the evolution of these guidelines provides important context for clinicians navigating a rapidly changing treatment landscape and highlights the need for continued research to inform safe, effective, and equitable anemia care for patients with CKD.